P G Casali, N Abecassis, H T Aro, S Bauer, R Biagini, S Bielack, S Bonvalot, I Boukovinas, J V M G Bovee, T Brodowicz, J M Broto, A Buonadonna, E De Álava, A P Dei Tos, X G Del Muro, P Dileo, M Eriksson, A Fedenko, V Ferraresi, A Ferrari, S Ferrari, A M Frezza, S Gasperoni, H Gelderblom, T Gil, G Grignani, A Gronchi, R L Haas, B Hassan, P Hohenberger, R Issels, H Joensuu, R L Jones, I Judson, P Jutte, S Kaal, B Kasper, K Kopeckova, D A Krákorová, A Le Cesne, I Lugowska, O Merimsky, M Montemurro, M A Pantaleo, R Piana, P Picci, S Piperno-Neumann, A L Pousa, P Reichardt, M H Robinson, P Rutkowski, A A Safwat, P Schöffski, S Sleijfer, S Stacchiotti, K Sundby Hall, M Unk, F Van Coevorden, W T A van der Graaf, J Whelan, E Wardelmann, O Zaikova, J Y Blay, ESMO Guidelines Committee and EURACAN
2018-10-05
Annals of oncology : official journal of the European Society for Medical Oncology
Previous PostPanitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group
Next PostBone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
